Strides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation pursuant to Regulation 39 (3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 201523-12-2022
23-12-2022
Strides Pharma arm gets Rs 525-crore deferred consideration for Aussie deal, shares spike
Strides Pharma's step-down subsidiary in Singapore received AUD 94 million or Rs 525 crore as the deferred consideration for the sale of the Company's Australian operations in 2019. The proceeds will be utilized for deleveraging the balance sheet, the firm said in an exchange filing.22-12-2022
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Receipt of AUD 94 million on account of deferred consideration on the sale of the Company's Australian operations in 201922-12-2022
Strides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Compliance under Regulation 39 (3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 201512-12-2022
Strides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation pursuant to Regulation 39 (3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 201501-12-2022
Strides Pharma Science Ltd - 532531 - Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
With reference to above, please find enclosed the disclosure of Related Party Transactions, on consolidated basis, for the half year ended September 30, 2022. This is for your information and records.28-11-2022
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Earnings Call transcript pertaining to Unaudited Financial Results for the quarter and half-year ended September 30, 202222-11-2022
Buy Strides Pharma Sciences; target of Rs 450: Sharekhan
Sharekhan is bullish on Strides Pharma Sciences has recommended buy rating on the stock with a target price of Rs 450 in its research report dated November 15, 2022.21-11-2022
Strides Pharma arms gets USFDA approval for potassium-deficiency drug
The approval granted by the US Food Drug Administration (USFDA) to Strides Pharma Global Pte Ltd, Singapore, is for potassium chloride oral solution of strength 40 mEq/15mL (20 per cent), Strides Pharma Science (Strides) said in a regulatory filing.18-11-2022
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Strides receives USFDA approval for Potassium Chloride Oral Solution18-11-2022